Find research datasets worth reusing

restrictedMay 2022View details →

Overdracht van het grafmonument voor agent baas

Source: Europeana 4DCity URL: <a href="https://4dcity.org/imgupload/1652523788.46.jpg">https://4dcity.org/imgupload/1652523788.46.jpg</a> Original Image URL: <a href="https://api.europeana.eu/thumbnail/v2/url.json?uri=https%3A%2F%2Fwww.openbeelden.nl%2Fimages%2F1271711%2FOverdracht_van_het_grafmonument_voor_agent_baas_%25280_18%2529.png&type=VIDEO">https://api.europeana.eu/thumbnail/v2/url.json?uri=https%3A%2F%2Fwww.openbeelden.nl%2Fimages%2F1271711%2FOverdracht_van_het_grafmonument_voor_agent_baas_%25280_18%2529.png&type=VIDEO</a> Image-Metadata: Filename: 1652523788.46.jpg Image Dimensions: 360x288 Megapixels: 0.10 MP Filesize: 79.81 KB

restrictedcc-by-4.0Aug 2024View details →

Strategies for Flow Cytometric Profiling of BCR Immunoglobulin Heavy Chain Isotypes: A Comparative Assessment of Fc Receptor Blocking Agents

This study aims to assess the impact of FcR blocking reagents on detection of BCR IgH isotypes IgM, IgD, IgA1-2, and IgG1-4.  Blood samples were collected from healthy volunteers in lithium heparin tubes, followed by the isolation of PBMCs utilizing BioColl density gradient centrifugation. The blood samples were diluted at a ratio of 1:1 in PBS with a pH of 7.4 and then centrifuged at 800 g for 20 minutes at RT. The PBMC interphases were harvested and washed three times with PBS containing 2 mM EDTA. Subsequently, PBMCs were resuspended in cRPMI medium. PBMCs were treated with five different FcR blocking reagents prior to staining. For each donor, PBMCs were divided into two groups, with each group containing five samples. One group was stained directly with an immunophenotyping panel without being washed following the application of FCR blocking reagent. The other group was applied washing before staining. Ultimately, the samples were incubated with an 8-color immunophenotyping panel targeting B-cell markers: <table> <tbody> <tr> <td> Target </td> <td> Fluorochrome </td> <td> Producer </td> <td> Clone </td> <td> Isotype </td> <td> Dilution </td> </tr> <tr> <td> CD19 </td> <td> APC-eFluor780 </td> <td> eBioscience </td> <td> HIB19 </td> <td> Mouse, IgG1, kappa </td> <td> 1:100 </td> </tr> <tr> <td> IgM </td> <td> PerCP/Cy5.5 </td> <td> Biolegend </td> <td> MHM-88 </td> <td> Mouse, IgG1, kappa </td> <td> 1:100 </td> </tr> <tr> <td> IgD </td> <td> AF700 </td> <td> Biolegend </td> <td> IA6-2 </td> <td> Mouse IgG2a, kappa </td> <td> 1:100 </td> </tr> <tr> <td> IgA </td> <td> VioBlue </td> <td> Miltenyi </td> <td> IS11-8E10 </td> <td> Mouse, IgG1, kappa </td> <td> 1:200 </td> </tr> <tr> <td> IgA2 </td> <td> PE </td> <td> Miltenyi </td> <td> IS11-21E11 </td> <td> Mouse, IgG1, kappa </td> <td> 1:100 </td> </tr> <tr> <td> IgG1 </td> <td> AF488 </td> <td> AF488/Lumiprobe </td> <td> MH161-1 </td> <td> Mouse, IgG2b, kappa </td> <td> 1:600 </td> </tr> <tr> <td> IgG1 </td> <td> Dylight550 </td> <td> Dylight/Innova Bio </td> <td> MH161-1 </td> <td> Mouse, IgG2b, kappa </td> <td> 1:500 </td> </tr> <tr> <td> IgG2 </td> <td> Dylight550 </td> <td> Dylight/Innova Bio </td> <td> HP6002 </td> <td> Mouse, IgG1, kappa </td> <td> 1:100 </td> </tr> <tr> <td> IgG3 </td> <td> AF488 </td> <td> AF488/Lumiprobe </td> <td> MH163-1 (HP6095) </td> <td> Mouse, IgG2b, kappa </td> <td> 1:400 </td> </tr> <tr> <td> IgG4 </td> <td> APC </td> <td> Cytognos </td> <td> SAG4 </td> <td> Mouse, IgG1, kappa </td> <td> 1:400 </td> </tr> <tr> <td> CD3 </td> <td> BV605 </td> <td> Biolegend </td> <td> OKT3 </td> <td> Mouse IgG2a, kappa </td> <td> 1:200 </td> </tr> <tr> <td> CD14 </td> <td> BV605 </td> <td> Biolegend </td> <td> 63D3 </td> <td> Mouse, IgG1, kappa </td> <td> 1:200 </td> </tr> <tr> <td> CD16 </td> <td> BV605 </td> <td> Biolegend </td> <td> 3G8 </td> <td> Mouse, IgG1, kappa </td> <td> 1:200 </td> </tr> <tr> <td> Viability dye </td> <td> Zombie yellow </td> <td> Biolegend </td> <td>   </td> <td>   </td> <td> 1:100 </td> </tr> </tbody> </table> Cells were analyzed on a FACS Aria IIIu (Becton, Dickinson and Company, Franklin Lakes, NJ). B cells were gated as live ZombieYellow-CD3-CD14-CD16-CD19+ lymphocyte. IgM and IgD expression was used to differentiate class-switched (IgM-IgD-) and non-switched (IgM+IgD+) B cells. Next, the IgA+ population, gated from switched B cells, was segregated into IgA1+ (gated as IgA+IgA2-) and IgA2+ (IgA+IgA2+) B cells. The IgA- population was segregated into IgG1+, IgG2+, IgG3+ and IgG4+ B cells. Gates were set based on fluorescence minus one (FMO) controls. To evaluate the effectiveness of the different blocking reagents used in our study on preventing non-specific binding of mouse monoclonal antibodies (mAbs), PBMCs were incubated with isotype control antibodies. Mouse IgG1, IgG2a, and IgG2b antibodies, all conjugated with PE, were evaluated for their non-specific binding to CD14+ monocytes. Prior to staining, the cells were divided into two groups and were treated with FcR blocking reagent as mentioned above. The details concerning the reagents are below: <table> <tbody> <tr> <td> Target </td> <td> Fluorochrome </td> <td> Brand </td> <td> Clone </td> <td> Isotype </td> <td> Dilution </td> </tr> <tr> <td> IgG1 </td> <td> PE </td> <td> Biolegend </td> <td> MOPC-21 </td> <td> Mouse, IgG1, kappa </td> <td> 1:100 </td> </tr> <tr> <td> IgG2a </td> <td> PE </td> <td> Biolegend </td> <td> MOPC-173 </td> <td> Mouse IgG2a, kappa </td> <td> 1:100 </td> </tr> <tr> <td> IgGb </td> <td> PE </td> <td> Biolegend </td> <td> MPC-11 </td> <td> Mouse, IgG2b, kappa </td> <td> 1:100 </td> </tr> <tr> <td> CD14 </td> <td> BV605 </td> <td> Biolegend </td> <td> 63D3 </td> <td> Mouse, IgG1, kappa </td> <td> 1:200 </td> </tr> <tr> <td> Viability dye </td> <td> Zombie green </td> <td> Biolegend </td> <td>   </td> <td>   </td> <td> 1:100 </td> </tr> </tbody> </table> The analysis of all flow cytometry data was performed using FlowJo v10 software (BD Biosciences). Statistical analysis was conducted using GraphPad Prism 9 software (GraphPad, La Jolla, USA).

opennotspecifiedFeb 2008View details →

Figure 3. Bone marrow ICR mouse metaphase with many breaks and fragments after Mitomycin C in Comparative analysis of the karyotype sensitivities of Apodemus flavicollis and laboratory mice to DNA-damaging agents

Figure 3. Bone marrow ICR mouse metaphase with many breaks and fragments after Mitomycin C treatment.

opennotspecifiedOct 2018View details →

FIGURES 43–44 in Acarine biocontrol agents Neoseiulus californicus sensu Athias-Henriot (1977) and N. barkeri Hughes (Mesostigmata: Phytoseiidae) redescribed, their synonymies assessed, and the identity of N. californicus (McGregor) clarified based on examination of types

FIGURES 43–44. Neoseiulus californicus sensu Athias-Henriot (1977). Female: legs I and IV, based on a specimen with similar collection data to the holotype of N. wearnei (=N. californicus sensu Athias-Henriot; slide lot #41, Table 1). 43. Coxa to tibia of leg I; 44. Coxa to basitarsus of leg IV. Only a few designations of setae are indicated for clarity; other designations can be inferred from Figs 25–28.

opennotspecifiedOct 2018View details →

FIGURE 18 in Acarine biocontrol agents Neoseiulus californicus sensu Athias-Henriot (1977) and N. barkeri Hughes (Mesostigmata: Phytoseiidae) redescribed, their synonymies assessed, and the identity of N. californicus (McGregor) clarified based on examination of types

FIGURE 18. Variation in the shape of the spermathecae of N. usitatus (a–f) and N. huffakeri (g–h): (a) slide lot # 51 (Table 1); (b, c) lot # 50; (d–f) lot #52; (g) paratype of N. huffakeri, lot #48; (h) lot # 49. Legend: AU—Australia, CA—California (USA), SA—South Africa.

opennotspecifiedOct 2018View details →

FIGURE 17 in Acarine biocontrol agents Neoseiulus californicus sensu Athias-Henriot (1977) and N. barkeri Hughes (Mesostigmata: Phytoseiidae) redescribed, their synonymies assessed, and the identity of N. californicus (McGregor) clarified based on examination of types

FIGURE 17. Neoseiulus barkeri (including other nominal species that are jun. syn. of N. barkeri). Variation in the shape of the spermathecae of specimens from: (a) slide lot #5 (Table 1); (b) lot #4; (c) holotype of N. mckenziei, lot #9; (d, e) 'from type material' of N. barkeri, lot #8; (f–j) holotype and paratypes of N. picketti, lot #10; (k–m) lot #17; (n, o) lot #16; (p, q) lot #15; (r–t) paratypes of N. oahuensis, lot #11; (u–x) lot #12; (y) lot #14. All figures at the same scale, shown in (y). Abbreviations: CA—California (USA), CAN—Canada, FI—Finland, HA—Hawaii (USA), NJ—New Jersey (USA), SK—South Korea, UK—United Kingdom; calyx L—length of calyx, atrium L—length of atrium, W—width of atrium.

opennotspecifiedNov 2021View details →

Fig. 3 in Argyrotoxins A-C, a trisubstituted dihydroisobenzofuranone, a tetrasubstituted 2-hydroxyethylbenzamide and a tetrasubstitutedphenyl trisubstitutedbutyl ether produced by Alternaria argyroxiphii, the causal agent of leaf spot on African mahogany trees (Khaya senegalensis)

Fig. 3. Mnemonic scheme relating the absolute configuration and the sign of the A band in the ECD spectrum of biphenylamides. L = largest group, M = medium size group, S = smallest group.

opennotspecifiedMar 2022View details →

Fig. 4 in Geraniol and Citral as potential therapeutic agents targeting the HSP90 activity: An in silico and experimental approach

Fig. 4. Graphical representation showing the (A) rate of reaction vs concentration of different compounds (B) Screening of salts for ATPase inhibition, (C) ATPase activity inhibition by different salts in their optimized range ATPase activity inhibition by mixture of salts and essential oil components, (D) The effect of essential oil components individually and their mixture with Na+/K+ salts on ATPase activity (E) HSP90-ATPase activity was increased by Calcium sulfate. All of the experiments were done in triplicate, and the error bars reflect the standard error of the mean, with * p 0.05 being deemed a significant difference.

opennotspecifiedSep 2022View details →

Fig. 5 in Furostanol saponins from Asparagus racemosus as potential hypoglycemic agents

Fig. 5. Effect of furoasparoside A-F (1–6) on GLUT4 translocation to cell surface in L6-GLUT4myc myotubes. Cell were treated overnight with purified compounds at (a)10 μM (b) increasing concentrations and cell surface level of GLUT4myc was monitored. Data are mean ± SEM, n = 4, *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001 compared to control.

Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)

ClinicalTrials.gov study NCT06409481. IPD Sharing: NO. Countries: 0. Publications: 0.

Composite Repair Using Silane Coupling Agent

ClinicalTrials.gov study NCT06392685. IPD Sharing: Not stated. Countries: 0. Publications: 0.

Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)

ClinicalTrials.gov study NCT03086395. IPD Sharing: Not stated. Countries: 0. Publications: 0.

Comparative Evaluation of Three Pulpotomy Agents for Permanent Mature Molars With Irreversible Pulpitis

ClinicalTrials.gov study NCT06232941. IPD Sharing: NO. Countries: 0. Publications: 0.

Skeletal Muscle Index and a Neuromuscular Blocking Agent

ClinicalTrials.gov study NCT06740877. IPD Sharing: Not stated. Countries: 0. Publications: 0.

Local Host Modulating Agents Alendronate & Aloe Vera for Treatment of Furcation Defects in Chronic Periodontitis

ClinicalTrials.gov study NCT03204097. IPD Sharing: Not stated. Countries: 0. Publications: 0.

Clinical Evaluation of Some Local Antimicrobial Agents' Adjunctive Effects On Periodontal Parameters and Halitosis

ClinicalTrials.gov study NCT03468595. IPD Sharing: NO. Countries: 0. Publications: 0.

Clinical Efficacies of Different Agents in Molar-Incisor Hypomineralization

ClinicalTrials.gov study NCT06180369. IPD Sharing: Not stated. Countries: 0. Publications: 0.

A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Mye

ClinicalTrials.gov study NCT06597734. IPD Sharing: Not stated. Countries: 1. Publications: 0.

Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status

ClinicalTrials.gov study NCT07094893. IPD Sharing: NO. Countries: 0. Publications: 0.

Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC

ClinicalTrials.gov study NCT04754815. IPD Sharing: NO. Countries: 0. Publications: 0.